• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Oncogenic drivers effective at guiding lung adenocarcinoma therapy

byRavi ShahandPriyanka Vedak
May 22, 2014
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 Image: PD 

1. Oncogenic drivers were identified in 64% of lung adenocarcinomas. 

2. Median survival was longer in patients treated with therapies targeted at the oncogenic drivers. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Lung adenocarcinoma is the most common type of lung cancer diagnosed in the United States. Over half of these malignancies have identifiable mutations that are critical to the development of tumors, called actionable oncogenic drivers. The Lung Cancer Mutation Consortium (LCMC) has identified these drivers as actionable because targeted therapy against them has been shown to negate or protract the neoplastic process. The LCMC designed this study to determine the frequency of oncogenic drivers, deduce the practicality of routine analysis, and evidence the effectiveness of using genetic findings to guide treatment. It was found that 64% of lung adenocarcinomas had at least one actionable driver mutation and that therapy guided by these findings led to increased medical survival from time of diagnosis. Interestingly only 3% of tumors demonstrated more than one actionable oncogenic driver.

This study’s main limitation is that it is not a randomized trial. The two cohorts of patients receiving targeted therapy did not have equivalent risk factors. Patients receiving targeted therapy were younger and more likely to not have been smokers, among other disparities. Additionally, almost a quarter of participants were ineligible for targeted treatment as a result of inadequate availability of biopsy tissue. Nevertheless, despite these limitations, this study supports findings demonstrated by prior research regarding the promising role of targeted therapy in future cancer treatments.

Click to read the study, published today in JAMA

RELATED REPORTS

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Relevant Reading: A Genomics-Based Classification of Human Lung Tumors

In-Depth [prospective cohort]: This study was conducted by the LCMC and began in 2009 with a median follow-up time of 2 years. 34% of patients had never smoked and 64% had Stage IV cancer. A total of 623 of the 1007 enrolled patients that had studies to identify at least one oncogenic driver were positive. 733 enrolled patients had the full assay conducted to detect up to 10 drivers and revealed a driver in 64% of patients. Patients received therapy based on their oncologist’s recommendation and review by the LCMC. A total of 28% patients received targeted therapy and had a median survival range of 3.5 years (IQR 1.96-7.70). Patients with an oncogenic driver who had not received targeted therapy had a median survival range of 2.4 years (IQR, 0.88-6.20). KRAS, EGFR, and ALK were the most common drivers with occurrences of 25%, 17%, and 8% in this sample respectively.

More from this author: Genetic factors account for half of complete risk of autism spectrum disorders, Increased maternal BMI linked to higher fetal, neonate, and infant mortality,Tadalafil ineffective for erectile dysfunction following prostate radiotherapy, Age-adjusted D-dimer levels may rule out pulmonary embolism [ADJUST-PE trial], Warfarin beneficial in chronic kidney patients with atrial fibrillation

 ©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: lung cancer
Previous Post

Pasireotide effective in reducing postoperative pancreatic surgery complications

Next Post

Higher cost-sharing associated with delayed care for children’s asthma

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Fleischner Society Guidelines, 2005 Statement: Limited CT follow-up recommended for small, solitary, pulmonary nodules [Classics Series]

June 14, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Next Post
Rhinovirus, genes may interact to increase the risk of childhood asthma

Higher cost-sharing associated with delayed care for children’s asthma

Modulating lymphocyte populations decreases graft rejection in mice

Modulating lymphocyte populations decreases graft rejection in mice

Renal stones in women linked with increased risk of coronary heart disease

Lower rates of repeat intervention following ureteroscopy for kidney stones

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.